市場調查報告書
商品編碼
1533044
歐洲填充成品製造市場預測至 2030 年 - 區域分析 - 按產品、方式和最終用戶Europe Fill Finish Manufacturing Market Forecast to 2030 - Regional Analysis - by Product, Modality, and End User |
2022年歐洲填充飾面製造市場價值為24.7326億美元,預計2030年將達到47.725億美元;預計2022年至2030年複合年成長率為8.6%。
生物製品需求的增加推動歐洲填補成品製造市場
生物製劑佔最暢銷藥物的大部分,也是成長最快的製藥業領域之一。自大約 30 年前推出重組蛋白療法以來,整個生物製劑市場的年成長率超過 12%。此外,目前有超過 5,000 種生物製藥候選產品正在開發中。儘管生物製藥提供了可觀的利潤率,但高開發成本和複雜的生產方案是這些藥理學干預措施的發起者的主要關注點。因此,一些新創公司和製藥巨頭已開始將其業務營運的不同流程外包給合約服務提供者。此外,將工作外包給合約製造組織(CMO)和合約開發與製造組織(CDMO)可以減少資本投資的需求,提供更大的生產能力,縮短產品上市時間,並降低與產品相關的風險。商業化。
填充完成是生產過程的最後一步,也是藥品生產中最關鍵的階段之一。生物製劑需要特殊的程序和設備來進行填充操作,以確保產品的完整性和安全性。因此,對生物製品需求的成長導致對靈活的無菌填充技術的同等需求。製藥商與合約服務提供者合作,利用他們在最新灌裝技術方面的經驗和專業知識。目前約有 180 家公司為各種生物製品提供灌裝製造服務。這些合約製造公司的 350 多家灌裝工廠遍布各個地區。
歐洲填充飾面製造市場概覽
德國的市場參與者正在採用有機和無機成長策略來擴大和成長市場。例如,2020 年 7 月,總部位於德國拉芬斯堡的合約開發和製造組織 (CDMO) Vetter 宣布,正在投資額外的填充/加工產能,購買奧地利的臨床製造基地。
同樣,齊格飛集團與德國免疫治療公司 Biopharmaceutical New Technologies 簽署了合作和供應協議,大規模灌裝和包裝商業數量的創新性 COVID-19 候選疫苗 BNT162b2。成功獲得批准後,BioNTech與美國製藥公司輝瑞公司合作開發的疫苗將從2021年中期起由齊格飛在其哈默爾恩工廠進行灌裝。此外,位於德國的領先生物製藥合約開發和製造組織 (CDMO) Rentschler Biotechnologie GmbH 與無菌灌裝和完成服務的獨立專家 Rentschler Fill Solutions GmbH 宣佈建立戰略合作夥伴關係,以提供新的最先進的先進的填充和加工設施以及生物製藥產品的一站式解決方案,以滿足Rentschler Biotechnologie 客戶的要求。
歐洲填充成品製造市場收入及 2030 年預測(百萬美元)
歐洲填充飾面製造市場細分
歐洲填充飾面製造市場根據產品、模式、最終用戶和國家進行細分。根據產品,歐洲灌裝製造市場分為消耗品和儀器。到2022年,消耗品細分市場將佔據更大的市場佔有率。
依模式分類,歐洲填充成品製造市場分為重組蛋白、單株抗體、疫苗、細胞療法及生物療法、基因療法等。 2022 年,疫苗領域佔據最大的市場。
就最終用戶而言,歐洲填充劑製造市場分為合約製造組織、生物製藥公司等。 2022 年,合約製造組織細分市場佔據最大的市場佔有率。
根據國家/地區,歐洲填充飾面製造市場分為英國、德國、法國、義大利、西班牙和歐洲其他地區。 2022 年,德國在歐洲填充飾面製造市場佔有率中佔據主導地位。
Becton Dickinson and Co、Gerresheimer AG、Groninger and Co GmbH、IMA Industria Macchine Automatiche SpA、Maquinaria Industrial Dara SL、Nipro Medical Europe NV、NNE AS、Optima Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SG 、和West Pharmaceutical Services Inc 是歐洲填充劑製造市場上的一些領先企業。
The Europe fill finish manufacturing market was valued at US$ 2,473.26 million in 2022 and is expected to reach US$ 4,772.50 million by 2030; it is estimated to grow at a CAGR of 8.6% from 2022 to 2030.
Elevating Demand for Biologics Drives Europe Fill Finish Manufacturing Market
Biologics constitute a majority of the top-selling drugs, and they represent one of the fastest-growing pharmaceutical industry segments. Since the launch of recombinant protein-based therapies ~30 years ago, the overall biologics market has grown at an annual rate of more than 12%. Further, over 5,000 biopharmaceutical product candidates are currently under development. Although biopharmaceuticals offer significant profit margins, high development costs and complex production protocols are the key concerns of the sponsors of these pharmacological interventions. As a result, several start-ups and pharmaceutical giants have begun outsourcing different processes of their business operations to contract service providers. Moreover, outsourcing jobs to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) reduces the requirement of capital investments, provides access to larger production capacities, decreases the time-to-market of products, and lowers risks associated with the commercialization of products.
Fill finish is the final step in the production process, and it is one of the most crucial stages of drug manufacturing. Biologics require special procedures and equipment for fill finish operations to ensure product integrity and safety. Thus, the rise in demand for biologics has resulted in an equivalent need for flexible aseptic fill finish technologies. Pharmaceutical drug manufacturers collaborate with contract service providers to leverage their experience and expertise in the latest fill finish technologies. Fill finish manufacturing services are currently provided by approximately 180 companies for a variety of biologics. They are located in over 350 fill finish factories for these contract manufacturing companies across various geographic regions.
Europe Fill Finish Manufacturing Market Overview
The market players in Germany are adopting organic and inorganic growth strategies for market expansion and growth. For instance, in July 2020, Vetter, the contract development and manufacturing organization (CDMO), headquarters in Ravensburg, Germany, announced that it is investing in additional fill/finish capacity with the purchase of a clinical manufacturing site in Austria.
Similarly, The Siegfried Group signed a cooperation and supply agreement with Biopharmaceutical New Technologies, a German immunotherapy company, for the large-scale filling and packaging of commercial quantities of BNT162b2, an innovative COVID-19 vaccine candidate. Following successful approval, the vaccine developed by BioNTech in cooperation with Pfizer, an American pharmaceutical company, will be filled by Siegfried at its Hameln site from mid-2021 onwards. Also, Rentschler Biotechnologie GmbH, leading contract development and manufacturing organization (CDMO) for biopharmaceuticals located in Germany, and Rentschler Fill Solutions GmbH, an independent specialist for aseptic fill and finish services, announced a strategic partnership to provide new state-of-the-art fill and finish facilities and one-stop solutions for biopharmaceutical products to meet the requirements of Rentschler Biotechnologie's clients.
Europe Fill Finish Manufacturing Market Revenue and Forecast to 2030 (US$ Million)
Europe Fill Finish Manufacturing Market Segmentation
The Europe fill finish manufacturing market is segmented based on product, modality, end user, and country. Based on product, the Europe fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment held a larger market share in 2022. Furthermore, the consumables is sub segmented into prefilled syringes, glass vial/plastic vials, cartridges, and others.
By modality, the Europe fill finish manufacturing market is segmented into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. The vaccines segment held the largest market share in 2022.
In terms of end user, the Europe fill finish manufacturing market is categorized into contract manufacturing organizations, biopharmaceutical companies, and others. The contract manufacturing organizations segment held the largest market share in 2022.
Based on country, the Europe fill finish manufacturing market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe fill finish manufacturing market share in 2022.
Becton Dickinson and Co, Gerresheimer AG, Groninger and Co GmbH, IMA Industria Macchine Automatiche SpA, Maquinaria Industrial Dara SL, Nipro Medical Europe NV, NNE AS, Optima Packaging Group Gmbh, Schott AG, SGD SA, Stevanato Group SpA, Syntegon Technology GmbH, and West Pharmaceutical Services Inc are some of the leading players operating in the Europe fill finish manufacturing market.